PubMed Health⌕ Search

PubMed · 7044726

Loop transverse colostomy. The case against.

Abstract

All large-bowel stomas (198) performed between 1970 and 1980 in a community hospital were reviewed. Twenty-nine stomas were loop transverse colostomies. There were five deaths, a complication rate related to the stoma of 28 per cent, and only 18 patients ever achieved colostomy closure. Our conclusions are as follows: (1) transverse colostomy is a holdover from the past; (2) "temporary" loop colostomy is a misnomer; (3) all colostomies should be end-bearing and matured primarily; (4) blind surgery invites tragedy; (5) loop transverse colostomy is a risky first stage with little benefit; (6) every colostomy should be placed as near as possible to the disease process; and (7) resection of the disease is the ideal first stage.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M J Winkler, P A Volpe. Loop transverse colostomy. The case against.. https://doi.org/10.1007/bf02553605

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Crohn's disease.

Crohn's disease is a relapsing systemic inflammatory disease, mainly affecting the gastrointestinal tract with extraintestinal manifestations and associated immune disorders. Genome wide association studies identified susceptibility loci that--triggered by environmental factors--result in a disturbed innate (ie, disturbed intestinal barrier, Paneth cell dysfunction, endoplasmic reticulum stress, defective unfolded protein response and autophagy, impaired recognition of microbes by pattern recognition receptors, such as nucleotide binding domain and Toll like receptors on dendritic cells and macrophages) and adaptive (ie, imbalance of effector and regulatory T cells and cytokines, migration and retention of leukocytes) immune response towards a diminished diversity of commensal microbiota. We discuss the epidemiology, immunobiology, amd natural history of Crohn's disease; describe new treatment goals and risk stratification of patients; and provide an evidence based rational approach to diagnosis (ie, work-up algorithm, new imaging methods [ie, enhanced endoscopy, ultrasound, MRI and CT] and biomarkers), management, evolving therapeutic targets (ie, integrins, chemokine receptors, cell-based and stem-cell-based therapies), prevention, and surveillance.

Colonic Diseases↗